评论 来源:证券时报·e公司 时间:2023-01-30 17:55:55
(相关资料图)
证券时报e公司讯,针对新冠口服药获批后市场关注的问题,君实生物方面向e公司记者表示,民得维会在获批后立即投产,尽全力加速各项事务,尽快实现发货及落地销售,以期尽早让药品来到患者手中。目前定价还在与相关部门积极沟通中,将按照国家相关要求进行申报及测算,形成合理定价。根据国家相关规定,民得维将被纳入临时医保药品目录。
标签: 君实生物
下一篇:最后一页
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
22-09-30
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30
23-01-30